#### **AFRICAN VACCINE REGULARY FORUM**

In strengthening capacity of african ethical review committees and national regulatory agencies

Samba Cor Sarr Vice Chair of AVAREF, with contribution of Akanmori Dicky from WHO/ Afro Stakeholder meeting, Antwerp; 29 November 2013





REGIONAL OFFICE FOR Africa



Plenary presentations by product developers/regulators/researchers, Task team meetings, Joint reviews,.

## Country members of AVAREF

- Botswana,
- Burkina Faso,
- Republic Democratic of Congo(RDC)
- Republic of Congo Congo Brazza)
- Guinea equatoriale
- Ethiopia
- Ghana
- Kenya
- Malawi
- Mali
- Mozambique

- Niger
- Nigeria
- Republic of centrafic
- Senegal
- Sierra Leone
- South Africa
- Tanzania
- Uganda
- Zambia
- Countries contacted to become AVAREF members : Ivory Coast, Benin, Guinea

## Partners and countries support AVAREF

- WHO/AFRO( secretariat)
- WHO/HQ
- GSK, Belgium
- Health Canada
- Gates Fondation/USA
- PATH Malaria Vaccine Institute/USA
- AERAS/USA
- EDCTP

- EMEA
- European Union
- African Union
- The list is not completed,
- During our meetings, we use 3 languages: French, Portugese, English, the documents published by AVAREF are also on 3 languages
- Website: <u>www.avaref.net</u>



Informal structure allows rapid and dynamic response as per needs identified AVAREF: an effective initiative to stimulate progress towards regulatory harmonization of clinical trials

- Channels of communication among African regulators and with regulators from developed countries have created confidence, strength and willingness to harmonize processes
- Model regulatory procedures developed and adopted by many Countries
- Joint reviews and joint inspections conducted (Conjugate meningitis A (MenAfriVac and Malaria (RTS,S) vaccines
- Enthusiasm from countries for further developments:
  - integration of ethical review, regulation and registration of clinical trials
  - development of African Common Clinical Trial Document and other guidelines

#### **Roles and Responsibilities**

#### **Ethics** Committees

- Review and approve human research studies
- Audit sites to ensure compliance with GCP/GLP
- Review data

#### National Regulatory Authorities

- Review CTAs for products for use in humans
- Approve importation of medicinal products for use in humans
- Inspect manufacturing facilities to ensure compliance with GMP
- Review CTDs and provide MA
- Review data and ensure PMS

#### Lifecycle Approach Model





## Submissions & Reviews of CTAs





## Review and approvals

Countries	Documents used	Duration for reviews	Type of submission	Require ments
Ghana, Tanzania, South Africa, Gambia, Uganda, Kenya, Nigeria	Adaptations of the African Common Clinical Trial Document	30-60 days for review and approvals	Online submissions Pre-registration on a WHO primary registry before submission	Ethics approval requirement before review by NRA
Senegal	Own SOPs integrating the african clinical trial document	30 -90 days	Physical submission, online submission (tests)	Ethics approval requirement before review by NRA

## African Common Clinical Trials Guidance (ACCTG) documents

- Guidance to sponsors on clinical trial application procedure
- Guidance for evaluators
- Harmonized Guidance on "Good Clinical Practice" inspections
- Safety monitoring during Clinical Trials
- Importation & release of clinical batches
- Storage & exportation of clinical trials samples for testing
- Pre-selection of experts/reviewers
- Model Memorandum Of Understanding

African Common Clinical Trials Guidance (ACCTG) documents

#### Harmonized Good Clinical Practice (GCP) Guidelines for AVAREF countries Aug 2009

## Summary of 8<sup>th</sup> Meeting

- Regulatory pathway for submission of dossiers for RTS,S discussed with sponsors
- Update on malaria vaccine standards discussed
- Case study on causality assessment
- Case study on critical issues for evaluation of HIV vaccine CTAs
- Updates on CTAs reviewed and products registered

#### Lessons learned and perspectives

- High level of expertise and commitment exists in countries
- Mutual recognition and acceptance of common challenges provides incentive to create the space to work together: <u>www.avaref.net</u> ( testing)
- Capacity building activities (development of regulatory procedures for CTs, joint reviews and inspections) provided a foundation for:

a path towards harmonization

the design of "authentic learning" opportunities

- Capacity building activities should feed into institutional developing plans (IDPs).
- Developing SPOs about fees for submission and administration of the protocols( ethical and regulatory review,: working groups are established and must share their results before the next meeting
- Developing e-learning by improving collaboration with for example TRREE, COHRED, and so on
- Increasing ownership by countries signalled by:
  - confidence to identify and propose future joint initiatives
  - between meeting implementation of activities











# Thank you for your attention

